A randomized, double blind pilot study to assess the effects of losartan vs. atenolol on the biophysical properties of the aorta in patients with Marfan and Loeys-Dietz syndromes

International Journal of Cardiology

Volumn 179, Issue , 2015, Pages 470-475

  Sandor, George G S ^a   Alghamdi, Mohammed H ^a   Raffin, Leslie A ^a   Potts, Mary T ^a   Williams, Lindsey D ^a   Potts, James E ^a   Kiess, Marla ^a   Van Breemen, Casey ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Atenolol; Clinical trial; LoeysDietz syndrome; Losartan; Marfan syndrome; Vascular function

Indexed keywords

ATENOLOL; LOSARTAN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT;

ADOLESCENT; ADULT; AORTA; AORTA ROOT; ARTERIAL STIFFNESS; ARTERY BLOOD FLOW; ARTERY COMPLIANCE; ARTICLE; BIOPHYSICS; BODY HEIGHT; BODY MASS; BRACHIAL ARTERY; BRADYCARDIA; CLINICAL ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG SAFETY; ECHOCARDIOGRAPHY; FAINTNESS; FATIGUE; FEMALE; HEADACHE; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE SIZE; HUMAN; LOEYS DIETZ SYNDROME; MALE; MARFAN SYNDROME; PATIENT COMPLIANCE; PILOT STUDY; PULSE WAVE; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; THORAX PAIN; VASODILATATION; DRUG EFFECTS; LOEYS-DIETZ SYNDROME; PATHOPHYSIOLOGY; TREATMENT OUTCOME; VASCULAR ENDOTHELIUM;

ADOLESCENT; ADRENERGIC BETA-1 RECEPTOR ANTAGONISTS; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; AORTA; ATENOLOL; DOUBLE-BLIND METHOD; ECHOCARDIOGRAPHY; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; LOEYS-DIETZ SYNDROME; LOSARTAN; MALE; MARFAN SYNDROME; PILOT PROJECTS; PULSE WAVE ANALYSIS; TREATMENT OUTCOME;

EID: 84920693915     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2014.11.082     Document Type: Article

References (41)

1. J. De Backer, B. Loeys, and A. De Paepe Marfan and Marfan-like syndromes Artery Res. 3 2009 9 16
2. D.P. Judge, and H.C. Dietz Marfan's syndrome Lancet 366 2005 1965 1976
3. B.L. Loeys, H.C. Dietz, A.C. Braverman, B.L. Callewaert, J. De Backer, and R.B. Devereux The revised Ghent nosology for the Marfan syndrome J. Med. Genet. 47 2010 476 485
4. P.N. Robinson, and M. Godfrey The molecular genetics of Marfan syndrome and related microfibrillopathies J. Med. Genet. 37 2000 9 25
5. Y. von Kodolitsch, and P.N. Robinson Syndrome: an update of genetics, medical and surgical management Heart 93 2007 755 760
6. H.C. Dietz TGF-B in the pathogenesis and prevention of disease: a matter of aneurysmic proportions J. Clin. Invest. 120 2010 403 407
7. P. Matt, F. Schoenhoff, J. Habashi, T. Holm, C. Van Erp, and D. Loch Circulating transforming growth factor-B in Marfan syndrome Circulation 120 2009 526 532
8. B.L. Loeys, J. Chen, E.R. Neptune, D.P. Judge, M. Podowski, and T. Holm A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 and TGFBR2 Nat. Genet. 37 2005 275 281
9. J. Shores, K.R. Berger, E.A. Murphy, and R.E. Pyeritz Progression of aortic dilatation and the benefit of long-term β-adrenergic blockade in Marfan's syndrome N. Engl. J. Med. 330 1994 1335 1341
10. J.P. Habashi, D.P. Judge, T.M. Holm, R.D. Cohn, B.L. Loeys, and T.K. Cooper Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome Science 312 2006 117 121
11. B.S. Brooke, J.P. Habashi, D.P. Judge, N. Patel, B. Loeys, and H.C. Dietz Angiotensin II blockade and aortic-root dilation in Marfan's syndrome N. Engl. J. Med. 358 2008 2787 2795
12. H.-H. Chiu, M.-H. Wu, J.-K. Wang, C.-W. Lu, S.-N. Chiu, and C.-A. Chen Losartan added to B-blockade therapy for aortic root dilation in Marfan syndrome: a randomized, open-label pilot study Mayo Clin. Proc. 88 2013 271 276
13. C. Pees, F. Laccone, M. Hagl, V. DeBrauwer, E. Moser, and I. Michel-Behnke Usefulness of Losartan on the size of the ascending aorta in an unselected cohort of children, adolescents, and young adults with Marfan syndrome Am. J. Cardiol. 112 2013 1477 1483
14. M. Groenink, A.W. den Hartog, R. Franken, T. Radonic, V. de Waard, and J. Timmermans Losartan reduces aortic dilation rate in adults with Marfan syndrome: a randomized controlled trial Eur. Heart J. 34 2013 3491 3500
15. D. Detaint, P. Aegerter, F. Tubach, I. Hoffman, H. Plauchu, and Y. Dulac Rationale and design of a randomized clinical trial (Marfan Sartan) of angiotensin II receptor blocker therapy versus placebo in individuals with Marfan syndrome Arch. Cardiovasc. Dis. 103 2010 317 325
16. F.I. Gambarin, V. Favalli, A. Serio, M. Regazzi, M. Pasotti, and C. Klersy Rationale and design of a trial evaluating the effects of losartan vs. nebivolol vs. The association of both on the progression of aortic root dilation in Marfan syndrome with FBN1 gene mutations J. Cardiovasc. Med. 10 2009 354 362
17. R.V. Lacro, H.C. Dietz, L.M. Wruck, T.J. Bradley, S.D. Colan, and R.B. Devereux Rationale and design of a randomized clinical trial of β-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome Am. Heart J. 154 2007 624 631
18. K. Moberg, S. De Nobele, D. Devos, E. Goetghebeur, P. Segers, and B. Trachet The Ghent Marfan trial - a randomized, double-blind placebo controlled trial with losartan in Marfan patients treated with β-blockers Int. J. Cardiol. 157 2012 354 358
19. T. Radonic, P. de Witte, M.J.H. Baars, A.H. Zwinderman, B.J.M. Mulder, and M. Groenink Losartan therapy in adults with Marfan syndrome: study protocol of the multi-center randomized controlled COMPARE trial Trials 11 2010
20. T.J. Bradley, J.E. Potts, M.T. Potts, A.M. DeSouza, and G.G.S. Sandor Echocardiographic Doppler assessment of the biophysical properties of the aorta in pediatric patients with the Marfan syndrome Am. J. Cardiol. 96 2005 1317 1321
21. K. Hirata, F. Triposkiadis, E. Sparks, J. Bowen, C.F. Wooley, and H. Boudoulas The Marfan syndrome: abnormal elastic properties J. Am. Coll. Cardiol. 18 1991 57 63
22. A.W.Y. Chung, K. Au Yeung, S.F. Cortes, G.G.S. Sandor, D.P. Judge, and H.C. Dietz Endothelial dysfunction and compromised eNOS/AKT signaling in the thoracic aorta during the progression of Marfan syndrome Br. J. Pharmacol. 150 2007 1075 1083
23. M. Takata, E. Amiya, M. Watanabe, K. Omori, Y. Imai, and D. Fujita Impairment of flow-mediated dilation correlates with aortic dilation in patients with Marfan syndrome Heart Vessels 29 2014 478 485
24. D.G. Wilson, M.F. Bellamy, M.W. Ramsey, J. Goodfellow, M. Brownlee, and S. Davies Endothelial function in Marfan syndrome. Selective impairment of flow-mediated vasodilation Circulation 99 1999 909 915
25. A.A. Ahimastos, A. Aggarwal, K.M. D'Orsa, M.F. Formosa, A.J. White, and R. Savarirayan Effect of perindopril on large artery stiffness and aortic root diameter in patients with Marfan syndrome JAMA 298 2007 1539 1547
26. A. Williams, D. Kenny, D. Wilson, G. Fagenello, M. Nelson, and F. Dunstan Effects of atenolol, perindopril and verapamil on haemodynamic and vascular function in Marfan syndrome - a randomized, double-blind, crossover trial Eur. J. Clin. Invest. 42 2012 891 899
27. A.P. Patrianakos, D. Karakitsos, E. de Groot, F.I. Parthenakis, E.K. Daphnis, and P.E. Vardas Alteration of proximal aorta biophysical properties in patients with end stage renal disease Heart 92 2006 228 232
28. G.G. Sandor, T. Hishitani, R.E. Petty, M.T. Potts, A. Desouza, and E. Desouza A novel Doppler echocardiographic method of measuring the biophysical properties of the aorta in pediatric patients J. Am. Soc. Echocardiogr. 16 2003 745 750
29. K.A. Myers, M.T. Leung, M. Terri Potts, J.E. Potts, and G.G. Sandor Noninvasive assessment of vascular function and hydraulic power and efficiency in pediatric Fontan patients J. Am. Soc. Echocardiogr. 26 2013 1221 1227
30. F.C.P. Yin, K.P. Brin, C.-T. Ting, and R.E. Pyeritz Arterial hemodynamic indexes in Marfan's syndrome Circulation 79 1989 854 862
31. A. De Paepe, R.B. Devereux, H.C. Dietz, R.C.M. Hennekam, and R.E. Pyeritz Revised diagnostic criteria for the Marfan syndrome Am. J. Med. Genet. 62 1996 417 426
32. T.J. Bradley, J.E. Potts, M.T. Potts, A. DeSouza, S.K. Lee, and G.G.S. Sandor Identifying early changes in children at-risk for cardiovascular disease: echo-Doppler assessment of the biophysical properties of the aorta in children born small for gestational age J. Pediatr 156 2010 388 392
33. G. Jondeau, P. Boutouyrie, P. Lacolley, B. Laloux, O. Dubourg, and J.-P. Bourdarias Central pulse pressure is a major determinant of ascending aorta dilation in Marfan syndrome Circulation 99 1999 2677 2681
34. G.M. London, B. Pannier, A.P. Guerin, S.J. Marchais, M.E. Safar, and J.L. Cuche Cardiac hypertrophy, aortic compliance, peripheral resistance, and wave reflection in end-stage renal disease. Comparative effects of ACE inhibition and calcium channel blockade Circulation 90 1994 2786 2796
35. A. Poppas, S.G. Shroff, C.E. Korcarz, J.U. Hibbard, D.S. Berger, and M.D. Lindheimer Serial assessment of the cardiovascular system in normal pregnancy Circulation 95 1997 2407 2415
36. Z. Liu, K.P. Brin, and F.C.P. Yin Estimation of total arterial compliance: an improved method and evaluation of current methods Am. J. Physiol 251 1986 H588 H600
37. R. Kelly, and D. Fitchett Noninvasive determination of aortic input impedance and external left ventricular power output: a validation and repeatability study of a new technique J. Am. Coll. Cardiol. 20 1992 952 963
38. S.E. Aeschlimann, C.K. Mitchell, and C.E. Korcarz Ultrasound brachial artery reactivity testing: technical considerations J. Am. Soc. Echocardiogr. 17 2004 697 699
39. R.B. Devereux, G. de Simone, D.K. Arnett, L.G. Best, E. Boerwinkle, and B.V. Howard Normal limits in relation to age, body size and gender of two-dimensional echocardiographic aortic root dimensions in persons greater than or equal to 15 years of age Am. J. Cardiol. 110 2012 1189 1194
40. R. Franken, A.W. den Hartog, V. de Waard, L. Engele, T. Radonic, and R. Lutter Circulating transforming growth factor-B as a prognostic biomarker in Marfan syndrome Int. J. Cardiol. 168 2013 2441 2446
41. D. Attias, C. Stheneur, C. Roy, G. Collod-Beroud, D. Detaint, and L. Faivre Comparison of clinical presentations and outcomes between patients with TGFBR2 and FBN1 mutations in Marfan syndrome and related disorders Circulation 120 2009 2541 2549